Tempus AI, Inc. - Class A Common Stock (TEM)

Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.

Oncology volume surged 32% while data licensing bookings topped $550 million year-to-date.

Tempus AI raised its outlook on 23% revenue growth, but most of its smaller net loss came from paper gains on stock it holds, not the core business.

Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBI

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Sale follows 30% rebound in the stock year to date.

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost

Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake.

Wood is known for being a tech-first investor.

Tempus AI's latest acquisition is looking like a great move.

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.

Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.

This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve

Tempus AI Inc. (NASDAQ: TEM) shares are trading lower Friday as traders digest post-earnings reset in expectations.

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a potentially powerful growth engine.

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI is growing fast, but the real debate is whether its healthcare data platform can justify the premium price investors are already paying.